À§¸¶ºñ Ä¡·á ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, Áúȯ ÀûÀÀÁõº°, À¯Çüº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº°
Gastroparesis Treatment Market, By Drug Class, By Disease Indication, By Type, By Route of Administration, By Distribution Channel, By Geography
»óǰÄÚµå
:
1672703
¸®¼Ä¡»ç
:
Coherent Market Insights
¹ßÇàÀÏ
:
2025³â 02¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹®
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
¼¼°èÀÇ À§¸¶ºñ Ä¡·á ½ÃÀåÀº 2025³â¿¡´Â 83¾ï 3,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2032³â¿¡´Â 115¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â¿¡ CAGR 4.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¸®Æ÷Æ® ¹üÀ§
¸®Æ÷Æ® »ó¼¼
±âÁØ¿¬µµ
2024
2025³â ½ÃÀå ±Ô¸ð
83¾ï 3,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ
2020-2024³â
¿¹Ãø ±â°£
2025-2032³â
¿¹Ãø ±â°£ : 2025-2032³â CAGR :
4.80%
2032³â °¡Ä¡ ¿¹Ãø
115¾ï 8,000¸¸ ´Þ·¯
µµÇ¥. À§¸¶ºñ Ä¡·á ½ÃÀå Á¡À¯À²(%), 2025³â Áö¿ªº°
¼¼°è À§ºÎÀü¸¶ºñ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº ´ç´¢º´°ú Ư¹ß¼º À§ºÎÀü¸¶ºñ À¯º´·ü Áõ°¡°¡ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. À§ºÎÀü ¸¶ºñ(À§ ¹èÃâ Áö¿¬)´Â À§°¡ ³»¿ë¹°À» ºñ¿ì´Â µ¥ ½Ã°£ÀÌ ³Ê¹« ¿À·¡ °É¸®´Â ¸¸¼ºÁúȯÀÔ´Ï´Ù. À§¸¶ºñ ȯÀÚ´Â ½Ä»ç ÈÄ ¸Þ½º²¨¿ò, ±¸Åä, º¹ºÎ ÆØ¸¸°¨, Æ÷¸¸°¨À» °æÇèÇÕ´Ï´Ù. ÇöÀç À§ºÎÀü¸¶ºñ¸¦ ¿ÏÄ¡ÇÒ ¼ö ÀÖ´Â Ä¡·á¹ýÀº ¾øÀ¸¸ç, ÇöÀç »ç¿ë °¡´ÉÇÑ Ä¡·á¹ýÀº Áõ»ó Á¶Àý¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. ½Å¾à °³¹ß°ú °ü·ÃµÈ ¿¬±¸°³¹ß Ȱµ¿ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù.
½ÃÀå ¿ªÇÐ:
¼¼°è À§ºÎÀü¸¶ºñ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº ´ç´¢º´ Àα¸ Áõ°¡, Ư¹ß¼º À§ºÎÀü¸¶ºñ À¯º´·ü Áõ°¡, À§ºÎÀü¸¶ºñ¿¡ ´ëÇÑ ±¹¹Î°ú ÀÇ»çÀÇ ÀÎ½Ä Áõ°¡ µîÀÇ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ±×·¯³ª °æ±¸¿ë ¾à¹°¿¡ µû¸¥ ȯÀÚ ¼øÀÀµµ ÀúÇÏ, È¿°úÀûÀÎ Ä¡·á¹ýÀÇ ºÎÀç, ¾à¼öó¸®ÀÇ ºÎÀÛ¿ë µîÀÌ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ´õ ³ªÀº È¿´É°ú ºÎÀÛ¿ëÀÌ ÀûÀº ½Å¾àÀÇ °³¹ßÀº ½ÃÀå¿¡ À¯¸®ÇÑ ¼ºÀå ±âȸ¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.
º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡
¼¼°èÀÇ À§ºÎÀü¸¶ºñ Ä¡·áÁ¦ ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇßÀ¸¸ç, 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» Á¶»çÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¸ÅÃâ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.
ÀÌ º¸°í¼´Â ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è À§ºÎÀü ¸¶ºñ Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ °³¿äÀ» Á¦°øÇÕ´Ï´Ù.
º» Á¶»çÀÇ ´ë»óÀÌ µÇ´Â ÁÖ¿ä ±â¾÷¿¡´Â Abbott Laboratories, Medtronic, Mylan, Pfizer, Johnson &Johnson Services, Bausch Health, Antrotrans, Alembic Pharmaceuticals µîÀÌ Æ÷ÇԵ˴ϴÙ.
ÀÌ º¸°í¼ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
¼¼°è À§¸¶ºñ Ä¡·á ½ÃÀå º¸°í¼´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è À§¸¶ºñ Ä¡·áÁ¦ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç
Á¦2Àå ½ÃÀå Àü¸Á
Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®
½ÃÀå ¿ªÇÐ
¿µÇ⠺м®
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
±ÔÁ¦ ½Ã³ª¸®¿À
Á¦Ç° ¹ß¸Å/½ÂÀÎ
PEST ºÐ¼®
PORTERÀÇ »ê¾÷ ºÐ¼®
ÇÕº´°ú Àμö ½Ã³ª¸®¿À
Á¦4Àå ¼¼°èÀÇ À§¸¶ºñ Ä¡·á ½ÃÀå, ¾àÁ¦ Ŭ·¡½ºº°, 2020-2032³â, (10¾ï ´Þ·¯)
¼ÒȰü ¿îµ¿ ÃËÁøÁ¦
Ç×±¸ÅäÁ¦
ÇÁ·ÎÅæ ÆßÇÁ ÀúÇØÁ¦
±âŸ(º¸Åø¸®´®Åå½Å(º¸Å彺) ÁÖ»ç µî)
Á¦5Àå ¼¼°èÀÇ À§¸¶ºñ Ä¡·á ½ÃÀå, Áúȯ ÀûÀÀÁõº°, 2020-2032³â, (10¾ï ´Þ·¯)
´ç´¢º´¼º À§¸¶ºñ
Ư¹ß¼º À§¸¶ºñ
¼ö¼úÈÄ À§¸¶ºñ
Á¦6Àå ¼¼°èÀÇ À§¸¶ºñ Ä¡·á ½ÃÀå, À¯Çüº°, 2020-2032³â, (10¾ï ´Þ·¯)
Á¦7Àå ¼¼°èÀÇ À§¸¶ºñ Ä¡·á ½ÃÀå, Åõ¿© °æ·Îº°, 2020-2032³â, (10¾ï ´Þ·¯)
Á¦8Àå ¼¼°èÀÇ À§¸¶ºñ Ä¡·á ½ÃÀå, À¯Åë ä³Îº°, 2020-2032³â, (10¾ï ´Þ·¯)
º´¿ø ¾à±¹
¼Ò¸Å ¾à±¹
¿Â¶óÀÎ ¾à±¹
Á¦9Àå ¼¼°èÀÇ À§¸¶ºñ Ä¡·á ½ÃÀå, Áö¿ªº°, 2020-2032³â(10¾ï ´Þ·¯)
ºÏ¹Ì
¶óƾ¾Æ¸Þ¸®Ä«
À¯·´
¾Æ½Ã¾ÆÅÂÆò¾ç
秵¾ÆÇÁ¸®Ä«
Á¦10Àå °æÀï ±¸µµ
Evoke Pharma, Inc.
Processa Pharmaceuticals, Inc.
Neurogastrx, Inc.
Vanda Pharmaceuticals Inc.
ANI Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
GlaxoSmithKline plc
Otsuka Holdings Co., Ltd.
CinDome Pharma, Inc.
PTC Therapeutics
Pfizer, Inc.
Teva Pharmaceutical Industries Ltd.
Atlantic Healthcare
Salix Pharmaceuticals
Rhythm Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc.
Medtronic plc
Bausch Health Companies Inc.
Sanofi S.A.
Á¦11Àå ¾Ö³Î¸®½ºÆ®ÀÇ ±ÇÀå»çÇ×
Á¦12Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý
Âü°í ¹®Çå
Á¶»ç ¹æ¹ý
ÃâÆÇ»ç ¼Ò°³
KSA
¿µ¹® ¸ñÂ÷
Global Gastroparesis Treatment Market is estimated to be valued at USD 8.33 Bn in 2025 and is expected to reach USD 11.58 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.8% from 2025 to 2032.
Report Coverage
Report Details
Base Year:
2024
Market Size in 2025:
USD 8.33 Bn
Historical Data for:
2020 To 2024
Forecast Period:
2025 To 2032
Forecast Period 2025 to 2032 CAGR:
4.80%
2032 Value Projection:
USD 11.58 Bn
Figure. Gastroparesis Treatment Market Share (%), By Region 2025
Global gastroparesis treatment market growth is driven by rising prevalence of diabetes and idiopathic gastroparesis. Gastroparesis, or delayed stomach emptying, is a chronic disorder, in which the stomach takes too long to empty its contents. Patients suffering from gastroparesis experience nausea, vomiting, bloating and fullness after eating. Currently, there is no cure for gastroparesis and the available treatment options focus on managing the symptoms. Rising research and development activities related to new drug development can drive the market growth.
Market Dynamics:
Global gastroparesis treatment market growth is driven by factors such as increasing diabetic population, rising prevalence of idiopathic gastroparesis, growing awareness about gastroparesis among people and physicians. However, poor patient compliance associated with oral medication, non-availability of effective treatment and side effects of drug therapies can hamper the market growth. Development of novel drugs with better efficacy and less side effects can offer lucrative growth opportunities in the market.
Key features of the study:
This report provides in-depth analysis of the global gastroparesis treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global gastroparesis treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Abbott Laboratories, Medtronic, Mylan, Pfizer, Johnson & Johnson Services, Bausch Health, Antrotrans, Alembic Pharmaceuticals
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global gastroparesis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global gastroparesis treatment market
Detailed Segmentation-
Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
Prokinetic Agents
Antiemetic Drugs
Proton Pump Inhibitors
Others (Botulinum Toxin Injections, etc.)
Disease Indication Insights (Revenue, USD Bn, 2020 - 2032)
Diabetes Gastroparesis
Idiopathic Gastroparesis
Post-surgical Gastroparesis
Type Insights (Revenue, USD Bn, 2020 - 2032)
Over-the-Counter Drugs
Prescription Drugs
Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regional Insights (Revenue, USD Bn, 2020 - 2032)
North America
U.S.
Canada
Latin America
Brazil
Argentina
Mexico
Rest of Latin America
Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
GCC Countries
Israel
Rest of Middle East
Africa
South Africa
North Africa
Central Africa
Key Players Insights
Evoke Pharma, Inc.
Processa Pharmaceuticals, Inc.
Neurogastrx, Inc.
Vanda Pharmaceuticals Inc.
ANI Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
GlaxoSmithKline plc
Otsuka Holdings Co., Ltd.
CinDome Pharma, Inc.
PTC Therapeutics
Pfizer, Inc.
Teva Pharmaceutical Industries Ltd.
Atlantic Healthcare
Salix Pharmaceuticals
Rhythm Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc.
Medtronic plc
Bausch Health Companies Inc.
Sanofi S.A.
Table of Contents
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Global Gastroparesis Treatment Market, By Drug Class
Global Gastroparesis Treatment Market, By Disease Indication
Global Gastroparesis Treatment Market, By Type
Global Gastroparesis Treatment Market, By Route of Administration
Global Gastroparesis Treatment Market, By Distribution Channel
Global Gastroparesis Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
4. Global Gastroparesis Treatment Market, By Drug Class, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Prokinetic Agents
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Antiemetic Drugs
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Proton Pump Inhibitors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others (Botulinum Toxin Injections, etc.)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Gastroparesis Treatment Market, By Disease Indication, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Diabetes Gastroparesis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Idiopathic Gastroparesis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Post-surgical Gastroparesis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Gastroparesis Treatment Market, By Type, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021- 2032
Segment Trends
Over-the-Counter Drugs
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Prescription Drugs
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Gastroparesis Treatment Market, By Route of Administration, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Injectables
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Nasal
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Gastroparesis Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Gastroparesis Treatment Market, By Region, 2020 - 2032, (USD Bn)
Introduction
Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
Market Y-o-Y Growth Analysis (%), 2021- 2032, e (USD Bn)
Regional Trends
North America
Introduction
Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Disease Indication, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
Latin America
Introduction
Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Disease Indication, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
Brazil
Argentina
Mexico
Rest of Latin America
Europe
Introduction
Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Disease Indication, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Disease Indication, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Introduction
Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Disease Indication, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
GCC Countries
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Disease Indication, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Country/Sub-region, 2020 - 2032, (USD Bn)
South Africa
North Africa
Central Africa
10. Competitive Landscape
Evoke Pharma, Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Processa Pharmaceuticals, Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Neurogastrx, Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Vanda Pharmaceuticals Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
ANI Pharmaceuticals, Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Takeda Pharmaceutical Company Limited
GlaxoSmithKline plc
Otsuka Holdings Co., Ltd.
CinDome Pharma, Inc.
PTC Therapeutics
Pfizer, Inc.
Teva Pharmaceutical Industries Ltd.
Atlantic Healthcare
Salix Pharmaceuticals
Rhythm Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc.
Medtronic plc
Bausch Health Companies Inc.
Sanofi S.A.
11. Analyst Recommendations
Wheel of Fortune
Analyst View
Coherent Opportunity Map
12. References and Research Methodology
References
Research Methodology
About us
°ü·ÃÀÚ·á